Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence

Clinical Pharmacology and Therapeutics

Volumn 75, Issue 1, 2004, Pages 34-48

  Montoya, Ivan D ^b   Gorelick, David A ^a   Preston, Kenzie L ^b   Schroeder, Jennifer R ^b   Umbricht, Annie ^b   Cheskin, Lawrence J ^b   Lange, W Robert ^b   Contoreggi, Carlo ^b   Johnson, Rolley E ^b   Fudala, Paul J ^b  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BENZOYLECGONINE; BUPRENORPHINE; COCAINE; KAPPA OPIATE RECEPTOR ANTAGONIST; METHADONE; MORPHINE; MU OPIATE RECEPTOR AGONIST; OPIATE; PLACEBO;

ADULT; ARTICLE; BACKACHE; CLINICAL TRIAL; COCAINE DEPENDENCE; COMORBIDITY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; DRUG TOLERABILITY; DRUG URINE LEVEL; DRUG WITHDRAWAL; EAR DISEASE; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; MUSCULOSKELETAL DISEASE; MYALGIA; NECK PAIN; NOSE DISEASE; OPIATE ADDICTION; OUTCOMES RESEARCH; PATIENT COUNSELING; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RESPIRATORY TRACT DISEASE; RHINORRHEA; SIDE EFFECT; SKIN MANIFESTATION; STATISTICAL SIGNIFICANCE; THROAT DISEASE; TOOTH DISEASE; URINALYSIS; UROGENITAL TRACT DISEASE; WITHDRAWAL SYNDROME;

EID: 9144235399     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2003.09.004     Document Type: Article

References (53)

1. Ohtani M., Kotaki H., Sawada Y., Iga T. Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther. 272:1995;505-510.
2. FDA Talk Paper, T02-38. Subutex and Suboxone approved to treat opiate dependence. Rockville (MD): Food and Drug Administration (US); 2002. Available from: URL: www.fda.gov/bbs/topics/ANSWERS/2002/ANS01165.html.
3. Johnson R.E., Jaffe J.H., Fudala P.J. A controlled trial of buprenorphine treatment for opioid dependence. JAMA. 267:1992;2750-2755.
4. Schottenfeld R.S., Pakes J.R., Oliveto A., Ziedonis D., Kosten T.R. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry. 54:1997;713-720.
5. Kosten T.R., Schottenfeld R., Ziedonis D., Falcioni J. Buprenorphine versus methadone maintenance for opioid dependence. J Nerv Ment Dis. 181:1993;358-364.
6. Amass L., Kamien J.B., Mikulich S.K. Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. Drug Alcohol Depend. 58:2000;143-152.
7. Eissenberg T., Johnson R.E., Bigelow G.E., Walsh S.L., Liebson I.A., Strain E.C., et al. Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients. Drug Alcohol Depend. 45:1997;81-91.
8. Johnson R.E., Eissenberg T., Stitzer M.L., Strain E.C., Liebson I.A., Bigelow G.E. Buprenorphine treatment of opioid dependence clinical trial of daily versus alternate-day dosing . Drug Alcohol Depend. 40:1995;27-35.
9. O'Connor P.G., Oliveto A.H., Shi J.M., Triffleman E.G., Carroll K.M., Kosten T.R., et al. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am J Med. 105:1998;100-105.
10. Leri F., Bruneau J., Stewart J. Understanding polydrug use review of heroin and cocaine co-use . Addiction. 98:2003;7-22.
11. Mello N.K., Mendelson J.H., Bree M.P., Lukas S.E. Buprenorphine suppresses cocaine self-administration by rhesus monkeys. Science. 245:1989;859-862.
12. Mello N.K., Lukas S.E., Kamien J.B., Mendelson J.H., Drieze J., Cone E.J. The effects of chronic buprenorphine treatment on cocaine and food self-administration by rhesus monkeys. J Pharmacol Exp Ther. 260:1992;1185-1193.
13. Carroll M.E., Lac S.T. Effects of buprenorphine on self-administration of cocaine and a nondrug reinforcer in rats. Psychopharmacology. 106:1992;439-446.
14. Mello N.K., Negus S.S. The effects of buprenorphine on self-administration of cocaine and heroin "speedball" combinations and heroin alone by rhesus monkeys. J Pharmacol Exp Ther. 285:1998;444-456.
15. Mendelson J.H., Teoh S.K., Mello N.K., Ellingboe J. Buprenorphine attenuates the effects of cocaine on adrenocorticotropin (ACTH) secretion and mood states in man. Neuropsychopharmacology. 7:1992;157-162.
16. Kouri E.M., Lukas S.E., Mendelson J.H. P300 assessment of opiate and cocaine users effects of detoxification and buprenorphine treatment . Biol Psychiatry. 40:1996;617-628.
17. Foltin R.W., Fischman M.W. Effects of methadone or buprenorphine maintenance on the subjective and reinforcing effects of intravenous cocaine in humans. J Pharmacol Exp Ther. 278:1996;1153-1164.
18. Strain E.C., Stitzer M.L., Liebson I.A., Bigelow G.E. Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users. Psychopharmacology (Berl). 116:1994;401-406.
19. Kosten T.R., Kleber H.D., Morgan C. Role of opioid antagonists in treating intravenous cocaine abuse. Life Sci. 44:1989;887-892.
20. Kosten T.R., Kleber H.D., Morgan C. Treatment of cocaine abuse with buprenorphine. Biol Psychiatry. 26:1989;637-639.
21. Schottenfeld R.S., Pakes J., Ziedonis D., Kosten T.R. Buprenorphine dose-related effects on cocaine and opioid use in cocaine-abusing opioid-dependent humans . Biol Psychiatry. 34:1993;66-74.
22. Schottenfeld R.S., Pakes J.R., Oliveto A., Ziedonis D., Kosten T.R. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry. 54:1997;713-720.
23. Cohen J. Statistical power analysis for the behavioral sciences. 2002;Lawrence Erlbaum Associates, Hillsdale (NJ).
24. Babst D.V., Chambers C.D., Warner A. Patient characteristics associated with retention in a methadone maintenance program. Br J Addict Alcohol Other Drugs. 66:1971;195-204.
25. Brown B.S., DuPont R.L., Bass U.F. III, Brewster G.W., Glendinning S.T., Kozel N.J., et al. Impact of a large-scale narcotics treatment program a six month experience . Int J Addict. 8:1973;49-57.
26. Hser Y.I., Anglin M.D., Liu Y. A survival analysis of gender and ethnic differences in responsiveness to methadone maintenance treatment. Int J Addict. 25:1990;1295-1315.
27. McLellan A.T., Luborsky L., Woody G.E., O'Brien C.P. An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J Nerv Ment Dis. 168:1980;26-33.
28. Robins L.N., Helzer J.E., Ratcliff K.S., Seyfried W. Validity of the diagnostic interview schedule, version II DSM-III diagnoses . Psychol Med. 12:1982;855-870.
29. Derogatis L.R., Cleary P.A. Factorial invariance across gender for the primary symptom dimensions of the SCL-90. Br J Soc Clin Psychol. 16:1977;347-356.
30. Rounsaville B.J., Gawin F., Kleber H. Interpersonal psychotherapy adapted for ambulatory cocaine abusers. Am J Drug Alcohol Abuse. 11:1985;171-191.
31. Nich C., Carroll K. Now you see it, now you don't a comparison of traditional versus random-effects regression models in the analysis of longitudinal follow-up data from a clinical trial . J Consult Clin Psychol. 65:1997;252-261.
32. Mallinckrodt C.H., Clark W.S., David S.R. Accounting for dropout bias using mixed-effects models. J Biopharm Stat. 11:2001;9-21.
33. Naumova E.N., Must A., Laird N.M. Tutorial in biostatistics evaluating the impact of 'critical periods' in longitudinal studies of growth using piecewise mixed effects models . Int J Epidemiol. 30:2001;1332-1341.
34. Diggle P.J., Liang K.Y., Zeger S.L. Analysis of longitudinal data. 1994;Clarendon, Oxford (United Kingdom).
35. Delucchi K.L., Jones R.T., Batki S.L. Measurement properties of quantitative urine benzoylecgonine in clinical trials research. Addiction. 92:1997;297-302.
36. Batki S.L., Manfredi L.B., Jacob P. III, Jones R.T. Fluoxetine for cocaine dependence in methadone maintenance quantitative plasma and urine cocaine/benzoylecgonine concentrations . J Clin Psychopharmacol. 13:1993;243-250.
37. Auriacombe M., Franques P., Tignol J. Deaths attributable to methadone vs buprenorphine in France. [letter] JAMA. 285:2001;45.
38. Kosten T.R., Kleber H.D., Morgan C. Role of opioid antagonists in treating intravenous cocaine abuse. Life Sci. 44:1989;887-892.
39. Oliveto A.H., Feingold A., Schottenfeld R., Jatlow P., Kosten T.R. Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine vs methadone. Arch Gen Psychiatry. 56:2001;812-820.
40. Oliveto A., Kosten T., Schottenfeld R., Ziedonis D. Cocaine abuse among methadone-maintained patients. [letter] Am J Psychiatry. 150:1993;1755.
41. Perez de los Cobos J., Martin S., Etcheberrigaray A., Trujols J., Batlle F., Tejero A., et al. A controlled trial of daily versus thrice-weekly buprenorphine administration for the treatment of opioid dependence. Drug Alcohol Depend. 59:2000;223-233.
42. Amass L., Bickel W.K., Crean J.P., Blake J., Higgins S.T. Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans. Psychopharmacology (Berl). 136:1998;217-225.
43. Magura S., Rosenblum A. Leaving methadone treatment lessons learned, lessons forgotten, lessons ignored . Mt Sinai J Med. 68:2001;62-74.
44. Montoya I.D., Umbricht A., Preston K.L. Buprenorphine for human immunovirus-positive opiate-dependent patients. [letter] Biol Psychiatry. 38:1995;135-136.
45. Carrieri M.P., Vlahov D., Dellamonica P., Gallais H., Lepeu G., Spire B., et al. Use of buprenorphine in HIV-infected injection drug users negligible impact on virologic response to HAART. The Manif-2000 Study Group . Drug Alcohol Depend. 60:2000;51-54.
46. Chawarski M.C., Schottenfeld R.S., O'Connor P.G., Pakes J. Plasma concentrations of buprenorphine 24 to 72 hours after dosing. Drug Alcohol Depend. 55:1999;157-163.
47. Mendelson J., Jones R.T., Fernandez I., Welm S., Melby A.K., Baggott M.J. Buprenorphine and naloxone interactions in opiate-dependent volunteers. Clin Pharmacol Ther. 60:1996;105-114.
48. Nath R.P., Upton R.A., Everhart E.T., Cheung P., Shwonek P., Jones R.T., et al. Buprenorphine pharmacokinetics relative bioavailability of sublingual tablet and liquid formulations . J Clin Pharmacol. 39:1999;619-623.
49. Schuh K.J., Johanson C.E. Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet. Drug Alcohol Depend. 56:1999;55-60.
50. Johnson R.E., Chutuape M.A., Strain E.C., Walsh S.L., Stitzer M.L., Bigelow G.E. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med. 343:2000;1290-1297.
51. Ling W., Charuvastra C., Collins J.F., Batki S., Brown L.S. Jr, Kintaudi P., et al. Buprenorphine maintenance treatment of opiate dependence a multicenter, randomized clinical trial . Addiction. 93:1998;475-486.
52. Petitjean S., Stohler R., Deglon J.J., Livoti S., Waldvogel D., Uehlinger C., et al. Double-blind randomized trial of buprenorphine and methadone in opiate dependence. Drug Alcohol Depend. 62:2001;97-104.
53. Lamb S.J., Greenlick M.R., McCarty D. Bridging the gap between practice and research: forging partnerships with community-based drug and alcohol treatment. 1998;National Academy Press, Washington.